Richard A. Van Etten - Publications

Affiliations: 
Harvard University, Cambridge, MA, United States 
Area:
Cell Biology, Molecular Biology, Oncology

54 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Kumar R, Pereira RS, Zanetti C, Minciacchi VR, Merten M, Meister M, Niemann J, Dietz MS, Rüssel N, Schnütgen F, Tamai M, Akahane K, Inukai T, Oellerich T, Kvasnicka HM, ... ... Van Etten RA, et al. Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia. Leukemia. PMID 32439895 DOI: 10.1038/s41375-020-0866-1  0.427
2017 Gu S, Sayad A, Chan G, Yang W, Lu Z, Virtanen C, Van Etten RA, Neel BG. SHP2 is required for BCR-ABL1-induced hematologic neoplasia. Leukemia. PMID 28804122 DOI: 10.1038/leu.2017.250  0.475
2016 Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, ... Van Etten RA, et al. Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia. Haematologica. PMID 27927766 DOI: 10.3324/Haematol.2016.152710  0.316
2016 Gu S, Chan WW, Mohi G, Rosenbaum J, Sayad A, Lu Z, Virtanen C, Li S, Neel BG, Van Etten RA. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Blood. PMID 26773044 DOI: 10.1182/Blood-2015-06-653006  0.516
2015 Jena N, Sheng J, Hu JK, Li W, Zhou W, Lee G, Tsichlis N, Pathak A, Brown N, Deshpande A, Luo C, Hu GF, Hinds PW, Van Etten RA, Hu MG. CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T cell acute lymphoblastic leukemia. Leukemia. PMID 26707936 DOI: 10.1038/Leu.2015.353  0.306
2015 Mughal TI, Barbui T, Abdel-Wahab O, Kralovics R, Jamieson C, Kvasnicka HM, Mullaly A, Rampal R, Mesa R, Kiladjian JJ, Deininger M, Prchal J, Hehlmann R, Saglio G, Van Etten RA. Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leukemia & Lymphoma. 56: 1938-48. PMID 25330439 DOI: 10.3109/10428194.2014.974594  0.353
2014 Hsieh MY, Van Etten RA. IKK-dependent activation of NF-κB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1. Blood. 123: 2401-11. PMID 24464015 DOI: 10.1182/Blood-2014-01-547943  0.382
2014 Mughal TI, Girnius S, Rosen ST, Kumar S, Wiestner A, Abdel-Wahab O, Kiladjian JJ, Wilson WH, Van Etten RA. Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leukemia & Lymphoma. 55: 1968-79. PMID 24206094 DOI: 10.3109/10428194.2013.863307  0.316
2013 Ahmed W, Van Etten RA. Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2013: 189-200. PMID 24319181 DOI: 10.1182/asheducation-2013.1.189  0.341
2013 Krause DS, Fulzele K, Catic A, Sun CC, Dombkowski D, Hurley MP, Lezeau S, Attar E, Wu JY, Lin HY, Divieti-Pajevic P, Hasserjian RP, Schipani E, Van Etten RA, Scadden DT. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nature Medicine. 19: 1513-7. PMID 24162813 DOI: 10.1038/Nm.3364  0.333
2012 Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, Hennighausen L, Zaleskas VM, Van Etten RA. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood. 119: 3550-60. PMID 22234689 DOI: 10.1182/blood-2011-12-397554  0.353
2011 Hu MG, Deshpande A, Schlichting N, Hinds EA, Mao C, Dose M, Hu GF, Van Etten RA, Gounari F, Hinds PW. CDK6 kinase activity is required for thymocyte development. Blood. 117: 6120-31. PMID 21508411 DOI: 10.1182/Blood-2010-08-300517  0.447
2011 Chan WW, Wise SC, Kaufman MD, Ahn YM, Ensinger CL, Haack T, Hood MM, Jones J, Lord JW, Lu WP, Miller D, Patt WC, Smith BD, Petillo PA, Rutkoski TJ, ... ... Van Etten RA, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 19: 556-68. PMID 21481795 DOI: 10.1016/J.Ccr.2011.03.003  0.492
2011 Van Etten RA, Koschmieder S, Delhommeau F, Perrotti D, Holyoake T, Pardanani A, Mesa R, Green T, Ibrahim AR, Mughal T, Gale RP, Goldman J. The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. Haematologica. 96: 590-601. PMID 21242185 DOI: 10.3324/Haematol.2010.035675  0.304
2009 Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, Van Etten RA, Donato N, Hunter A, Dinsdale D, Tirrò E, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. The Journal of Clinical Investigation. 119: 1109-23. PMID 19363292 DOI: 10.1172/Jci35660  0.366
2009 Zhong J, Gavrilescu LC, Molnár A, Murray L, Garafalo S, Kehrl JH, Simon AR, Van Etten RA, Kyriakis JM. GCK is essential to systemic inflammation and pattern recognition receptor signaling to JNK and p38. Proceedings of the National Academy of Sciences of the United States of America. 106: 4372-7. PMID 19246396 DOI: 10.1073/pnas.0812642106  0.445
2008 Ko J, Patel N, Ikawa T, Kawamoto H, Frank O, Rivera RR, Van Etten RA, Murre C. Suppression of E-protein activity interferes with the development of BCR-ABL-mediated myeloproliferative disease. Proceedings of the National Academy of Sciences of the United States of America. 105: 12967-72. PMID 18725623 DOI: 10.1073/Pnas.0805073105  0.314
2007 Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews. Cancer. 7: 332-44. PMID 17457301 DOI: 10.1038/Nrc2106  0.335
2007 Van Etten RA. Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. The Journal of Experimental Medicine. 204: 461-5. PMID 17353369 DOI: 10.1084/jem.20062335  0.45
2006 Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, Van Etten RA. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. Plos One. 1: e18. PMID 17183644 DOI: 10.1371/Journal.Pone.0000018  0.441
2005 Derkinderen P, Scales TM, Hanger DP, Leung KY, Byers HL, Ward MA, Lenz C, Price C, Bird IN, Perera T, Kellie S, Williamson R, Noble W, Van Etten RA, Leroy K, et al. Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 6584-93. PMID 16014719 DOI: 10.1523/Jneurosci.1487-05.2005  0.382
2005 Shannon K, Van Etten RA. JAKing up hematopoietic proliferation. Cancer Cell. 7: 291-3. PMID 15837617 DOI: 10.1016/J.Ccr.2005.04.002  0.33
2005 Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, Van Etten RA, Dörken B, le Coutre P. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells, Molecules & Diseases. 34: 181-5. PMID 15727903 DOI: 10.1016/j.bcmd.2004.11.006  0.346
2004 Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Jordan A, Hildebrandt B, Schmidt CA, Van Etten RA, Dörken B, Le Coutre P. Combined administration of imatinib mesylate and ionizing radiation leads to increased radiosensitivity in the human glioblastoma cell line RuSi RS1. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1564. PMID 28015729 DOI: 10.1200/jco.2004.22.14_suppl.1564  0.362
2004 Million RP, Harakawa N, Roumiantsev S, Varticovski L, Van Etten RA. A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Molecular and Cellular Biology. 24: 4685-95. PMID 15143164 DOI: 10.1128/MCB.24.11.4685-4695.2004  0.768
2004 Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Hallek M, Van Etten RA, Li S. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nature Genetics. 36: 453-61. PMID 15098032 DOI: 10.1038/Ng1343  0.466
2004 Roumiantsev S, Krause DS, Neumann CA, Dimitri CA, Asiedu F, Cross NC, Van Etten RA. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell. 5: 287-98. PMID 15050920  0.48
2003 Van Etten RA. c-Abl regulation: a tail of two lipids. Current Biology : Cb. 13: R608-10. PMID 12906815  0.315
2003 Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Molecular Cell. 12: 27-37. PMID 12887890  0.511
2002 Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proceedings of the National Academy of Sciences of the United States of America. 99: 10700-5. PMID 12149456 DOI: 10.1073/Pnas.162140299  0.748
2002 Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K, Gesbert F, Iwasaki H, Li S, Van Etten RA, Gu H, Griffin JD, Neel BG. Critical role for Gab2 in transformation by BCR/ABL Cancer Cell. 1: 479-492. PMID 12124177 DOI: 10.1016/S1535-6108(02)00074-0  0.568
2002 Goldberg Z, Vogt Sionov R, Berger M, Zwang Y, Perets R, Van Etten RA, Oren M, Taya Y, Haupt Y. Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. The Embo Journal. 21: 3715-27. PMID 12110584 DOI: 10.1093/Emboj/Cdf384  0.387
2002 Million RP, Aster J, Gilliland DG, Van Etten RA. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood. 99: 4568-77. PMID 12036890 DOI: 10.1182/Blood-2001-12-0244  0.749
2002 Dash AB, Williams IR, Kutok JL, Tomasson MH, Anastasiadou E, Lindahl K, Li S, Van Etten RA, Borrow J, Housman D, Druker B, Gilliland DG. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proceedings of the National Academy of Sciences of the United States of America. 99: 7622-7. PMID 12032333 DOI: 10.1073/Pnas.102583199  0.528
2001 Brasher BB, Roumiantsev S, Van Etten RA. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain. Oncogene. 20: 7744-52. PMID 11753652 DOI: 10.1038/Sj.Onc.1204978  0.743
2001 Li S, Couvillon AD, Brasher BB, Van Etten RA. Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling. The Embo Journal. 20: 6793-804. PMID 11726515 DOI: 10.1093/Emboj/20.23.6793  0.759
2001 Smith KM, Van Etten RA. Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization. The Journal of Biological Chemistry. 276: 24372-9. PMID 11320088 DOI: 10.1074/jbc.M100786200  0.469
2001 Tomasson MH, Williams IR, Li S, Kutok J, Cain D, Gillessen S, Dranoff G, Van Etten RA, Gilliland DG. Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3 Blood. 97: 1435-1441. PMID 11222391 DOI: 10.1182/Blood.V97.5.1435  0.427
2001 Roumiantsev S, de Aos IE, Varticovski L, Ilaria RL, Van Etten RA. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood. 97: 4-13. PMID 11133737 DOI: 10.1182/BLOOD.V97.1.4  0.603
2000 Brasher BB, Van Etten RA. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. The Journal of Biological Chemistry. 275: 35631-7. PMID 10964922 DOI: 10.1074/Jbc.M005401200  0.74
2000 Million RP, Van Etten RA. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood. 96: 664-70. PMID 10887132  0.769
2000 Tomasson MH, Sternberg DW, Williams IR, Carroll M, Cain D, Aster JC, Ilaria RL, Van Etten RA, Gilliland DG. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. The Journal of Clinical Investigation. 105: 423-32. PMID 10683371 DOI: 10.1172/Jci8902  0.437
1999 Wang Y, Ripperger J, Fey GH, Samols D, Kordula T, Wetzler M, Van Etten RA, Baumann H. Modulation of hepatic acute phase gene expression by epidermal growth factor and Src protein tyrosine kinases in murine and human hepatic cells Hepatology. 30: 682-697. PMID 10462375 DOI: 10.1002/Hep.510300318  0.468
1999 Li S, Ilaria RL, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. The Journal of Experimental Medicine. 189: 1399-412. PMID 10224280 DOI: 10.1084/Jem.189.9.1399  0.718
1999 Ilaria RL, Hawley RG, Van Etten RA. Dominant Negative Mutants Implicate STAT5 in Myeloid Cell Proliferation and Neutrophil Differentiation Blood. 93: 4154-4166. DOI: 10.1182/BLOOD.V93.12.4154.412K15_4154_4166  0.394
1998 Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS, Peeters P, Van Rompaey L, Van Etten RA, Ilaia R, Marynen P, Gilliland DG. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes Embo Journal. 17: 5321-5333. PMID 9736611 DOI: 10.1093/Emboj/17.18.5321  0.459
1998 Okuda K, D’Andrea A, Van Etten R, Griffin J. The C-Terminus of c-Abl Is Required for Proliferation and Viability Signaling in a c-Abl/Erythropoietin Receptor Fusion Protein Blood. 92: 3848-3856. DOI: 10.1182/blood.v92.10.3848.422k44_3848_3856  0.48
1997 Wen ST, Van Etten RA. The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes & Development. 11: 2456-67. PMID 9334312 DOI: 10.1101/GAD.11.19.2456  0.536
1997 Ilaria RL, Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. The Journal of Biological Chemistry. 271: 31704-10. PMID 8940193 DOI: 10.1074/jbc.271.49.31704  0.48
1995 Ilaria RJ, Van Etten R. The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells Blood. 86: 3897-3904. DOI: 10.1182/BLOOD.V86.10.3897.BLOODJOURNAL86103897  0.53
1993 Wetzler M, Talpaz M, Van Etten RA, Hirsh-Ginsberg C, Beran M, Kurzrock R. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. The Journal of Clinical Investigation. 92: 1925-39. PMID 8408645 DOI: 10.1172/Jci116786  0.335
1992 Mayer BJ, Jackson PK, Van Etten RA, Baltimore D. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo. Molecular and Cellular Biology. 12: 609-18. PMID 1370711 DOI: 10.1128/Mcb.12.2.609  0.581
1991 Scott ML, Van Etten RA, Daley GQ, Baltimore D. v-abl causes hematopoietic disease distinct from that caused by bcr-abl. Proceedings of the National Academy of Sciences of the United States of America. 88: 6506-10. PMID 1862078 DOI: 10.1073/Pnas.88.15.6506  0.306
1990 Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (New York, N.Y.). 247: 824-30. PMID 2406902 DOI: 10.1126/Science.2406902  0.383
Show low-probability matches.